![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 9
Zeitschriftenartikel
Linder, Andreas; Bothe, Viktoria; Linder, Nicolas; Schwarzlmueller, Paul; Dahlstrom, Frank; Bartenhagen, Christoph; Dugas, Martin; Pandey, Dharmendra; Thorn-Seshold, Julia; Boehmer, Daniel F. R.; Koenig, Lars M.; Kobold, Sebastian; Schnurr, Max; Raedler, Johannes; Spielmann, Giulia; Karimzadeh, Hadi; Schmidt, Andreas; Endres, Stefan und Rothenfusser, Simon
(30. April 2021):
Defective Interfering Genomes and the Full-Length Viral Genome Trigger RIG-I After Infection With Vesicular Stomatitis Virus in a Replication Dependent Manner.
In: Frontiers in Immunology, Bd. 12, 595390
[PDF, 2MB]
Ben Khaled, Najib; Piseddu, Ignazio; Boehmer, Daniel F. R.; Zierold, Sarah; Heinzerling, Lucie; Mayerle, Julia und De Toni, Enrico N.
(2021):
Checkpoint-Inhibition bei Tumorerkrankungen.
In: Onkologe, Bd. 27, Nr. 11: S. 1075-1084
Boehmer, Daniel F. R.; Formisano, Simone; Mann, Carina C. de Oliveira; Mueller, Stephan A.; Kluge, Michael; Metzger, Philipp; Rohlfs, Meino; Hoerth, Christine; Kocheise, Lorenz; Lichtenthaler, Stefan F.; Hopfner, Karl-Peter; Endres, Stefan; Rothenfusser, Simon; Friedel, Caroline C.; Duewell, Peter; Schnurr, Max und Koenig, Lars M.
(2021):
OAS1/RNase L executes RIG-I ligand-dependent tumor cell apoptosis.
In: Science Immunology, Bd. 6, Nr. 61, eabe2550
Magg, Thomas; Okano, Tsubasa; Koenig, Lars M.; Boehmer, Daniel F. R.; Schwartz, Samantha L.; Inoue, Kento; Heimall, Jennifer; Licciardi, Francesco; Ley-Zaporozhan, Julia; Ferdman, Ronald M.; Caballero-Oteyza, Andres; Park, Esther N.; Calderon, Brenda M.; Dey, Debayan; Kanegane, Hirokazu; Cho, Kazutoshi; Montin, Davide; Reiter, Karl; Griese, Matthias; Albert, Michael H.; Rohlfs, Meino; Gray, Paul; Walz, Christoph; Conn, Graeme L.; Sullivan, Kathleen E.; Klein, Christoph; Morio, Tomohiro und Hauck, Fabian
(2021):
Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency.
In: Science Immunology, Bd. 6, Nr. 60, eabf9564
Metzger, Philipp; Kirchleitner, Sabrina V.; Boehmer, Daniel F. R.; Hörth, Christine; Eisele, Angelika; Ormanns, Steffen; Gunzer, Matthias; Lech, Maciej; Lauber, Kirsten; Endres, Stefan; Duewell, Peter; Schnurr, Max und König, Lars M.
(2020):
Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
In: Cancer immunology, immunotherapy : CII, Bd. 69: S. 2101-2112
[PDF, 1MB]
Boehmer, Daniel F. R.; Koehler, Lisa M.; Magg, Thomas; Metzger, Philipp; Rohlfs, Meino; Ahlfeld, Julia; Rack-Hoch, Anita; Reiter, Karl; Albert, Michael H.; Endres, Stefan; Rothenfusser, Simon; Klein, Christoph; König, Lars M. und Hauck, Fabian
(2020):
A Novel Complete Autosomal-Recessive STAT1 LOF Variant Causes Immunodeficiency with Hemophagocytic Lymphohistiocytosis-Like Hyperinflammation.
In: Journal of Allergy and Clinical Immunology-in Practice, Bd. 8, Nr. 9: S. 3102-3111
Ruzicka, Michael; König, Lars M.; Formisano, Simone; Boehmer, Daniel F. R.; Vick, Binje; Heuer, Eva-M.; Meinl, Hanna; Kocheise, Lorenz; Zeitlhoefler, Marcus; Ahlfeld, Julia; Kobold, Sebastian; Endres, Stefan; Subklewe, Marion; Duewell, Peter; Schnurr, Max; Jeremias, Irmela; Lichtenegger, Felix S. und Rothenfusser, Simon
(2020):
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
In: Leukemia, Bd. 34, Nr. 4: S. 1017-1026
König, Lars M.; Boehmer, Daniel F. R.; Metzger, Philipp; Schnurr, Max; Endres, Stefan und Rothenfusser, Simon
(2020):
Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19.
In: Journal of Experimental Medicine, Bd. 217, Nr. 9, e20201342
Bek, Sarah; Stritzke, Florian; Wintges, Alexander; Nedelko, Tatiana; Boehmer, Daniel F. R.; Fischer, Julius C.; Haas, Tobias; Poeck, Hendrik und Heidegger, Simon
(2019):
Targeting intrinsic RIG-I signaling turns melanoma cells into type I interferon-releasing cellular antitumor vaccines.
In: Oncoimmunology, Bd. 8, Nr. 4, e1570779